Elevated levels of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with increased low-density lipoprotein (LDL) and worse cardiovascular outcomes. Antibodies to PCSK9 have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of LDL-cholesterol (LDL-C).

2021年9月1日 · PCSK9 inhibitors can help treat high cholesterol by directly modifying this gene to reduce the amount of LDL in your body. Learn about the PCSK9 gene, how PCSK9 inhibitors affect LDL...

The PCSK9 inhibitor blocks the PCSK9 enzyme, resulting in more LDL receptors available to remove LDL from the blood, which produces in a decrease in LDL blood levels.

2024年2月25日 · In the United States, 2 fully humanized monoclonal antibodies—alirocumab and evolocumab— have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, that inhibits intracellular PCSK9 synthesis.

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

2016年5月18日 · These antibodies target PCSK9, a protease that binds and promotes degradation of the LDL receptor, leading more LDL receptors on the surface of hepatocytes, and a lower level of serum LDL-C. A synergistic benefit of using PCSK9 inhibitors with statins is also proposed since statin therapy causes upregulation of PCSK9 levels in hepatocytes.

SDS-PAGE analysis of PCSK9 Biosimilar Recombinant monoclonal antibody (Product # MA5-59703). Samples were run under reducing (R) condition. The purity of the protein is greater than 90%. ... PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein is synthesized as a soluble ...

Monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) are an innovative LLT that has the ability to substantially reduce LDL-C levels.

PCSK9 (D7U6L) Rabbit mAb recognizes endogenous levels of total PCSK9 protein. Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln190 of human PCSK9 protein.

2024年9月6日 · Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody inhibitors have been shown to reduce low-density lipoprotein cholesterol (LDL-C) substantially. This study aimed to assess the real-world effectiveness of PCSK9 inhibitor therapy among patients with HeFH.